Moleculin Biotech (MBRX) Capital Expenditures (2016 - 2024)
Moleculin Biotech (MBRX) posted quarterly Capital Expenditures of $13000.0 for Q2 2024, down 13.33% year-over-year from $15000.0 in Q3 2023, and down 83.95% quarter-over-quarter from $81000.0 in Q4 2023.
Moleculin Biotech (MBRX) Capital Expenditures (2016 - 2024) Analysis & Trends
Moleculin Biotech's Capital Expenditures history runs 9 years deep, the most recent figure standing at $13000.0 for Q2 2024.
- In Q2 2024, Capital Expenditures fell 13.33% year-over-year to $13000.0; the TTM figure through Mar 2025 stood at $13000.0 (down 89.52% YoY), while the FY2024 annual figure was $13000.0, down 89.52% from the prior year.
- Capital Expenditures for Q2 2024 stood at $13000.0, down from $81000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $340000.0 in Q3 2020, with the low at -$360000.0 in Q4 2020.
- The 5-year median for Capital Expenditures is $18000.0 (2020), against an average of $20272.7.
- Peak annual rise in Capital Expenditures reached 2715.38% in 2020, while the deepest fall reached 1261.29% in 2020.
- Moleculin Biotech's Capital Expenditures stood at -$360000.0 in 2020, then soared by 105.28% to $19000.0 in 2021, then soared by 221.05% to $61000.0 in 2022, then soared by 32.79% to $81000.0 in 2023, then sank by 83.95% to $13000.0 in 2024.
- Business Quant data shows MBRX's Capital Expenditures at $13000.0 in Q2 2024, $81000.0 in Q4 2023, and $28000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 34.68 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.26 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 251.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -73.57 Mn |
| 10 | Moleculin Biotech | 3.35 Mn | 3.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 13,000.00 |
| Jun 30, 2024 | 13,000.00 |
| Dec 31, 2023 | 81,000.00 |
| Dec 31, 2023 | 81,000.00 |
| Sep 30, 2023 | 28,000.00 |
| Sep 30, 2023 | 28,000.00 |
| Jun 30, 2023 | 15,000.00 |
| Jun 30, 2023 | 15,000.00 |
| Jun 30, 2022 | 61,000.00 |
| Jun 30, 2022 | 61,000.00 |
| Mar 31, 2022 | 6,000.00 |
| Mar 31, 2022 | 6,000.00 |
| Dec 31, 2021 | 19,000.00 |
| Dec 31, 2021 | 19,000.00 |
| Dec 31, 2020 | -360,000.00 |
| Dec 31, 2020 | -360,000.00 |
| Sep 30, 2020 | 340,000.00 |
| Sep 30, 2020 | 340,000.00 |
| Jun 30, 2020 | 18,000.00 |
| Jun 30, 2020 | 18,000.00 |